InnoCare Announces Approval of the Next-Generation TRK Inhibitor Zurletrectinib in China



In the registrational clinical trial for patients with NTRK fusion-positive solid tumors, zurletrectinib demonstrated outstanding efficacy and a favorable safety profile. The study results showed an objective response rate (ORR) of 89.1%, a disease control rate (DCR) of 96.4%, and 24-month progression-free survival (PFS) and overall survival (OS) rates of 77.4% and 90.8% respectively. Read More



Source link

  • Related Posts

    'I love my job': A Canadian astronaut trains (and waits) to go to space

    Jenni Gibbons talks about becoming the third Canadian woman to become an astronaut, the job’s ups and downs, and why space exploration matters. Source link

    Son testifies in Hawaii doctor’s attempted murder trial

    IE 11 is not supported. For an optimal experience visit our site on another browser. Now Playing Son testifies in Hawaii doctor’s attempted murder trial 00:43 UP NEXT What it…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    From Frogspawn to Frog Sqwad: The Making of A Sticky, Snacky New Multiplayer Game

    From Frogspawn to Frog Sqwad: The Making of A Sticky, Snacky New Multiplayer Game

    'I love my job': A Canadian astronaut trains (and waits) to go to space

    'I love my job': A Canadian astronaut trains (and waits) to go to space

    FDA grants speedy approval to Eli Lilly's weight-loss pill for obesity

    FDA grants speedy approval to Eli Lilly's weight-loss pill for obesity

    See Nat Geo's Behind-the-Scenes Footage Inside the Artemis II Orion Spacecraft

    See Nat Geo's Behind-the-Scenes Footage Inside the Artemis II Orion Spacecraft

    Leicestershire sign seamer Yadvinder Singh on short-term deal

    Leicestershire sign seamer Yadvinder Singh on short-term deal

    United Airlines’ 10 Emptiest Long-Haul Routes Revealed

    United Airlines’ 10 Emptiest Long-Haul Routes Revealed